x
 
  • Mar 25 ,2021

    BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of the underwriters’ overallotment option to purchase 545,454 additional shares of common stock, at a public offering price of $11.00 per share. The gross proceeds to Gain from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Gain, were...

    Read More >

  • Mar 18 ,2021

    BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of 3,636,364 shares of its common stock at a price of $11.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on March 18, 2021 under the symbol “GANX.” The offering is expected to close on March 22, 2021 subject to customary closing conditions. The underwriters have a 30-day option to purchase up to an additional 545,454 shares of...

    Read More >

  • Mar 10 ,2021

    BETHESDA, Md., March 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial public offering of shares of its common stock. Gain is offering 3,636,364 shares of its common stock. The initial public offering price is expected to be between $10.00 and $12.00 per share, before underwriting discounts and commissions. In addition, Gain expects to grant the underwriters a 30-day option to purchase up to an additional 545,454...

    Read More >

 

MORE

 

MORE